In the US, 5.8 million people has Alzheimer’s disease in 2018, and will increase to 13.4 million by 2050. Worldwide the total AD patients will reach to 100 million by 2050.

There are no disease-modifying drugs ever approved by FDA in the USA nor around the world.

All clinical trials of AD drugs failed because they are designed to remove amyloid plaques, which are proven not to be the right target.